Gunn I. Meling

Gunn I. Meling

Auto-generated profile, based on publicly available information

Gunn I. Meling

Surgical Department, Faculty Division Akershus University Hospital, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
GLGuro E Lind
Guro E Lind
LTLin Thorstensen
Lin Thorstensen
TLTone Løvig
Tone Løvig
GMGunn I Meling
Gunn I Meling
RHRichard Hamelin
Richard Hamelin
RLRagnhild A Lothe
Ragnhild A Lothe
Tumor cell lines are commonly used as experimental tools in cancer research, but their relevance for the in vivo situation is debated. In a series of 11 microsatellite stable (MSS) and 9 microsatellite unstable (MSI) colon cancer cell lines and primary colon carcinomas (25 MSS and 28 MSI) with known ploidy stem line and APC, KRAS, and TP53 mutation status, we analyzed the promoter methylation of the following genes: hMLH1, MGMT, p16 INK4a (CDKN2A α-transcript), p14 ARF (CDKN2A β-transcript), APC, and E-cadherin (CDH1). We compared the DNA methylation profiles of the cell lines with those of the primary tumors. Finally, we examined if the epigenetic changes were associated with known genetic markers and/or clinicopathological variables.

31 December 2008 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
TATerje Ahlquist
Terje Ahlquist
GLGuro Elisabeth Lind
Guro Elisabeth Lind
VCVera L Costa
Vera L Costa
GMGunn I Meling
Gunn I Meling
MVMorten Vatn
Morten Vatn
RLRagnhild A Lothe
Ragnhild A Lothe
Background: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact. This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.The methylation status of eleven genes (ADAMTS1,CDKN2A,CRABP1,HOXA9,MAL,MGMT,MLH1,NR3C1,PTEN,RUNX3, andSCGB3A1) was determined in 154 tissue samples including normal mucosa, adenomas, and carcinomas of the colorectum. The gene-specific and widespread methylation status among the carcinomas was related to patient gender and age, and microsatellite instability status. Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI),BRAF-,KRAS-, andTP53mutation status.Results: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas. Widespread methylation was found in both adenomas and carcinomas. The promoters ofADAMTS1,MAL, andMGMTwere frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability. In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes. HypermethylatedCRABP1, MLH1,NR3C1,RUNX3, andSCGB3A1were shown to be identifiers of carcinomas with microsatellite instability. In agreement with the CIMP concept, MSI and mutatedBRAFwere associated with samples harboring hypermethylation of several target genes.Conclusion: MethylatedADAMTS1,MGMT, andMALare suitable as markers for early tumor detection.

3 January 2007 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
KKKristine Kleivi
Kristine Kleivi
GLGuro E Lind
Guro E Lind
CDChieu B Diep
Chieu B Diep
GMGunn I Meling
Gunn I Meling
LBLin T Brandal
Lin T Brandal
RLRagnhild A Lothe
Ragnhild A Lothe
Background: Despite the fact that metastases are the leading cause of colorectal cancer deaths, little is known about the underlying molecular changes in these advanced disease stages. Few have studied the overall gene expression levels in metastases from colorectal carcinomas, and so far, none has investigated the peritoneal carcinomatoses by use of DNA microarrays. Therefore, the aim of the present study is to investigate and compare the gene expression patterns of primary carcinomas (n = 18), liver metastases (n = 4), and carcinomatoses (n = 4), relative to normal samples from the large bowel. Results: Transcriptome profiles of colorectal cancer metastases independent of tumor site, as well as separate profiles associated with primary carcinomas, liver metastases, or peritoneal carcinomatoses, were assessed by use of Bayesian statistics. Gains of chromosome arm 5p are common in peritoneal carcinomatoses and several candidate genes (including PTGER4, SKP2, and ZNF622) mapping to this region were overexpressed in the tumors. Expression signatures stratified on TP53 mutation status were identified across all tumors regardless of stage. Furthermore, the gene expression levels for the in vivo tumors were compared with an in vitro model consisting of cell lines representing all three tumor stages established from one patient. Conclusion: By statistical analysis of gene expression data from primary colorectal carcinomas, liver metastases, and carcinomatoses, we are able to identify genetic patterns associated with the different stages of tumorigenesis.

17 March 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GLGuro Elisabeth Lind
Guro Elisabeth Lind
TATerje Ahlquist
Terje Ahlquist
MKMatthias Kolberg
Matthias Kolberg
MBMarianne Berg
Marianne Berg
MEMette Eknæs
Mette Eknæs
RLRagnhild A Lothe
Ragnhild A Lothe
Background: Tumor-derived aberrantly methylated DNA might serve as diagnostic biomarkers for cancer, but so far, few such markers have been identified. The aim of the present study was to investigate the potential of the MAL (T-cell differentiation protein) gene as an early epigenetic diagnostic marker for colorectal tumors. Methods: Using methylation-specific polymerase chain reaction (MSP) the promoter methylation status of MAL was analyzed in 218 samples, including normal mucosa (n = 44), colorectal adenomas (n = 63), carcinomas (n = 65), and various cancer cell lines (n = 46). Direct bisulphite sequencing was performed to confirm the MSP results. MAL gene expression was investigated with real time quantitative analyses before and after epigenetic drug treatment. Immunohistochemical analysis of MAL was done using normal colon mucosa samples (n = 5) and a tissue microarray with 292 colorectal tumors. Results: Bisulphite sequencing revealed that the methylation was unequally distributed within the MAL promoter and by MSP analysis a region close to the transcription start point was shown to be hypermethylated in the majority of colorectal carcinomas (49/61, 80%) as well as in adenomas (45/63, 71%). In contrast, only a minority of the normal mucosa samples displayed hypermethylation (1/23, 4%). The hypermethylation of MAL was significantly associated with reduced or lost gene expression in in vitro models. Furthermore, removal of the methylation re-induced gene expression in colon cancer cell lines. Finally, MAL protein was expressed in epithelial cells of normal colon mucosa, but not in the malignant cells of the same type. Conclusion: Promoter hypermethylation of MAL was present in the vast majority of benign and malignant colorectal tumors, and only rarely in normal mucosa, which makes it suitable as a diagnostic marker for early colorectal tumorigenesis.